❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Cancer Immunology ❭ Immunotherapy against solid cancers [Kyte] ❭ Research projects ❭

Research project overview

ALICE: A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer 

REPORT: Reirradiation and PD-1 blockade on recurrent squamous cell head and neck tumors

ICON: A randomized phase IIb study evaluating immunogenic chemotherapy combined with double immunological checkpoint blockade in patients with metastatic luminal B breast cancer 

 
Page visits: 2409
Scroll to top

Home Dept. of Cancer Immunology Immunotherapy against solid cancers [Kyte]

  • Group members
  • Research projects
  • Publications
  • Tweets
  • Available positions
  • News and Events

Recent publications

Beck C, Casey NP, Persiconi I, Moharrami NN, Sike A, Jin Y, Kyte JA (2023)
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
Biomedicines, 11 (2)
DOI 10.3390/biomedicines11020459, PubMed 36830995

Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A (2023)
How I treat endocrine-dependent metastatic breast cancer
ESMO Open, 8 (2), 100882 (in press)
DOI 10.1016/j.esmoop.2023.100882, PubMed 36806375

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103

More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Email: trond.olav.berg@rr-research.no

Cookie policy

Accessibility statement (in Norwegian)